NasdaqGS - Nasdaq Real Time Price USD

Bolt Biotherapeutics, Inc. (BOLT)

Compare

0.5000

-0.0035

(-0.70%)

At close: December 20 at 4:00:02 PM EST

0.4923

-0.01

(-1.54%)

After hours: December 20 at 4:10:19 PM EST

Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations

Bolt Biotherapeutics ( NASDAQ:BOLT ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.14m (down 55% from...

Simply Wall St. last month

BOLT
-0.70%
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -11.11% and 12.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

BOLT
-0.70%
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

BOLT) on Tuesday reported a loss of $15.2 million in its third quarter. The Redwood City, California-based company said it had a loss of 40 cents per share. The results did not meet Wall Street expectations.

Associated Press Finance last month

BOLT
-0.70%
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001 at the SITC 39th Annual MeetingBDC-4182 on track to start clinical trial in second quarter 2025Cash balance of $84.4 million as of September 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire last month

BOLT
-0.70%
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. last month

BOLT
-0.70%
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the tre

GlobeNewswire last month

BOLT
-0.70%
Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sof

GlobeNewswire 3 months ago

BOLT
-0.70%
Bolt Biotherapeutics to Participate in Upcoming September Conferences

REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)H.C. Wainwright 26th Annual Global Investment ConferenceCompany presentation available on

GlobeNewswire 3 months ago

BOLT
-0.70%
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingCash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developi

GlobeNewswire 4 months ago

BOLT
-0.70%
The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

Global stocks are surging. The MSCI ACWI Index, which encompasses both developed and emerging markets, reached another all-time high, continuing its record-breaking streak. This milestone is part of a broader trend in global equity markets, with 14 out of the world’s 20 largest stock exchanges recently setting new records. In contrast to this general market uplift, stocks with analyst uncertainty remain a notable exception, where divergent views among experts signal potential volatility and risk

InvestorPlace 6 months ago

BIDU

UAA

BOLT
-0.70%
Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...

Key updates include leadership changes, significant workforce reduction, and promising developments in cancer treatment trials.

GuruFocus.com 7 months ago

BOLT
-0.70%
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.

BioPharma Dive 7 months ago

BOLT
-0.70%
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Dev

GlobeNewswire 7 months ago

BOLT
-0.70%
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 7 months ago

BOLT
-0.70%
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapi

GlobeNewswire 8 months ago

BOLT
-0.70%
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website

GlobeNewswire 9 months ago

BOLT
-0.70%

Performance Overview

Return	BOLT	S&P 500
YTD	-55.36%	+24.34%
1-Year	-50.00%	+24.38%
3-Year	-89.01%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics to Participate in Upcoming September Conferences

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...

Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

Performance Overview